Predictive Technology Group, Inc. (PRED)
| Market Cap | 43.26M |
| Revenue (ttm) | 19.17M |
| Net Income (ttm) | n/a |
| Shares Out | 310.88M |
| EPS (ttm) | -0.23 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 209,463 |
| Open | 0.1420 |
| Previous Close | 0.1400 |
| Day's Range | 0.1350 - 0.1490 |
| 52-Week Range | 0.0300 - 0.5600 |
| Beta | -0.75 |
| Analysts | n/a |
| Price Target | n/a |
| Est. Earnings Date | n/a |
About PRED
Predictive Technology Group, Inc., together with its subsidiaries, develops and commercializes discoveries and technologies involved in novel molecular diagnostic, therapeutic, and human cellular and tissue-based products (HCT/Ps). It operates in two segments, Human Cellular and Tissues Products (HCT/Ps); and Diagnostics and Therapeutics. The company provides FertilityDX, a genetic testing service for couples experiencing infertility; ARTguide, a genetic test for women experiencing infertility because of endometriosis and other genetic conditio...
Financial Performance
In 2020, PRED's revenue was $24.44 million, a decrease of -43.80% compared to the previous year's $43.49 million. Losses were -$85.90 million, 456.9% more than in 2019.
Financial StatementsNews
Called to Account: SEC halts trading in two stocks amid claims about COVID-19 tests
Shares of two companies that a short seller alleged were making fraudulent claims about tests for COVID-19 were suspended from trading by the Securities and Exchange Commission on Wednesday, as the regu...